key: cord-0742420-9yb9a9vz
authors: Elezkurtaj, S.; Greuel, S.; Ihlow, J.; Michaelis, E.; Bischoff, P.; Kunze, C. A.; Sinn, B. V.; Gerhold, M.; Hauptmann, K.; Ingold-Heppner, B.; Miller, F.; Herbst, H.; Corman, V. M.; Martin, H.; Heppner, F. L.; Horst, D.
title: Causes of Death and Comorbidities in Patients with COVID-19
date: 2020-06-17
journal: nan
DOI: 10.1101/2020.06.15.20131540
sha: 130c18b70c5617aa352b88e3908346eab6831144
doc_id: 742420
cord_uid: 9yb9a9vz

Infection by the new corona virus strain SARS-CoV-2 and its related syndrome COVID-19 has caused several hundreds of thousands of deaths worldwide. Patients of higher age and with preexisting chronic health conditions are at an increased risk of fatal disease outcome. However, detailed information on causes of death and the contribution of comorbidities to death yet is missing. Here, we report autopsy findings on causes of death and comorbidities of 26 decedents that had clinically presented with severe COVID-19. We found that septic shock and multi organ failure was the most common immediate cause of death, often due to suppurative pulmonary infection. Respiratory failure due to diffuse alveolar damage presented as the most immediate cause of death in fewer cases. Several comorbidities, such as hypertension, ischemic heart disease, and obesity were present in the vast majority of patients. Our findings reveal that causes of death were directly related to COVID-19 in the majority of decedents, while they appear not to be an immediate result of preexisting health conditions and comorbidities. We therefore suggest that the majority of patients had died of COVID-19 with only contributory implications of preexisting health conditions to the mechanism of death.

More than 7.9 million confirmed cases of coronavirus disease 2019 and more than 434 thousand associated deaths have been counted around the globe by June 15, 2020 1 .

COVID-19 is caused by infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), a novel and highly contagious coronavirus strain that mostly spreads through respiratory droplets and that has first been identified in Wuhan, China 2 .

Some SARS-CoV-2 infections are asymptomatic while most cause mild to moderate illness with respiratory and flu-like symptoms, including fever, chills, cough and sore throat 3, 4 . However, a significant number of patients with COVID-19 develops critical illness and requires intensive care with mechanical ventilation or extracorporeal membrane oxygenation 5, 6 . Especially in these cases, the disease may ultimately be fatal 7 . While raw numbers of deaths suggest overall COVID-19 case-fatality rates of more than 5 % 1 , infection-fatality rates probably are lower and may range around 0.3-0.5 % 8 .

The risk of death from COVID-19 strongly depends on age and previous health conditions. Older patients and those with chronic comorbidities, such as cardiovascular disease, hypertension, diabetes, and pulmonary disease, are much more prone to critical and fatal disease outcomes 4,9 . These associations may contribute to an uncertainty to what extent COVID-19 or preexisting health conditions determined the time of a patient's death. Detailed information on the causality and mechanism of death, as well as the spectrum of comorbidities in cases with fatal outcome that will allow accurate assessment of the hazardous nature of COVID-19 yet is missing.

Autopsies are the gold standard for the analysis of medical conditions and causes of death. Few reports described damage to several organs due to COVID-19 on the morphological level.

However, while one study reported fatal pulmonary thromboembolism in few cases 10 , systematic information on immediate and underlying causes of death are scarce. Here, we present data on clinical and autoptic causes of death and comorbidities of 26 patients that had died after SARS-CoV-2 infection and COVID-19 in Berlin, Germany. Our findings reveal that causes of death were directly related to COVID-19 in most cases and not an immediate consequence of preexisting health conditions and comorbidities, i.e. these patients -despite often suffering from severe health conditions -would not have died in the absence of a SARS-CoV-2 infection at the given time point.

All rights reserved. No reuse allowed without permission.

(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. 

Data collection and statistical analysis were done with IBM SPSS Statistics, Version 23 (IBM, NY, USA). Age at death was presented as median with interquartile range (IQR) to account for deviations from normal distribution. Categorical variables were summarized as counts and percentages. Median time to death was analyzed using the Kaplan-Meier method. All rights reserved. No reuse allowed without permission.

(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. 

We analyzed 26 cases of patients that died after COVID-19 disease and that were autopsied at the Institute of Pathology of the Charité university hospital in Berlin. In all cases, SARS-CoV-2 infection was confirmed by PCR testing. Of the decedents, 17 were male and 9 were female.

One of the decedents was of Black ethnicity, while 25 were Caucasians. The median age at (Table 1) . Aside from lung involvement, acute renal failure was the second most prevalent organ failure and hemodialysis was necessary in 69.2 % of the patients. Furthermore, half of the patients presented with multi-organ failure, while acute liver failure was reported in 30.8 %. These findings indicated severe and complex courses of COVID-19 in these patients. An overview of the clinical characteristics is given in Table 1 .

To learn about clinical causes of death, we assessed legal death certificates of the 26 decedents. Most frequent immediate causes of death, documented in 19 cases (73.1 %), were infection related, and included sepsis, septic shock, or sepsis-related multi-organ failure in 16 cases (61.5 %), bacterial infections in two cases (7.7 %), and viral pneumonia in one case (3.8 %). Second most common were respiration-related causes of death, documented as respiratory insufficiency, hypoxia, or acute respiratory distress syndrome (ARDS) in four cases (15.4 %) .

Further individual immediate causes of death were pulmonary embolism and cardiovascular failure (3.8 % each).

In addition, clinical death certificates provided information on conditions leading to immediate causes of death and death-related underlying disease (Table 1) . Here, pulmonary disease in 22 decedents (84.6 %) was the most frequently documented condition leading to cause of death, which included pneumonia or viral pneumonia in 14 cases (53.8 %), and ARDS in eight cases (30.8 %). Importantly, when jointly considering conditions leading to cause of death and underlying disease, COVID-19, confirmed or suspected SARS-CoV-2 infection was documented All rights reserved. No reuse allowed without permission.

(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted June 17, 2020. . in a total of 23 cases (88.5 %), and thus in the vast majority of deceased patients. Other underlying diseases that were deemed clinically relevant for death included cancer in two cases (7.7 %), and individual cases of alcohol abuse, renal failure, COPD, or GvHD. Collectively, these data indicated that, from a clinical perspective, COVID-19 and infection-related disease were major contributors to patients' death in the majority of cases.

Clinical records also contained information on chronic comorbidities and further relevant health conditions. The median number of chronic comorbidities in these cases was four, and ranged from three to eight (Table 1) . Arterial hypertension was the most prevalent chronic condition in the decedents (65.4 %), followed by obesity (38.5 %), chronic ischemic heart disease (34.6 %), atrial fibrillation (26.9 %), and chronic obstructive pulmonary disease (23.1 %). Vascular conditions were specified as atherosclerosis (7.7 %) and cerebrovascular disease (15.4 %) . Of all patients, 15.4 % had diabetes type II, and chronic renal failure was noticed in 11.5 % of decedents. Active or non-active nicotine abuse was noted in 5 patients (19.2 %) and alcohol abuse in 3 patients (11.5 %). Further details are available from Table 1 . These data suggested severe chronic comorbidities and health conditions in the majority of patients that had died after COVID-19.

In order to investigate causes of death directly, we performed full body autopsies including histopathological workup on all 26 decedents. Based on assessment of pathological disease mechanisms and referring to clinical documentations of death, we defined immediate causes of death, conditions leading to cause of death, and underlying causes ( Table 2 ). As the most common immediate cause of death, we found septic shock and/or multi-organ failure in 8 patients (30.8 %), followed by suppurative pulmonary infections in five patients (19.2 %), including bacterial pneumonia with or without abscess formation, as well as infarct necrosis with signs of purulent bacterial superinfection. Right ventricular congestive heart failure or decompensation as immediate cause of death was present in four patients (15.4 %) . In five patients (19.2 %), respiratory failure or diffuse alveolar damage was the immediate cause of death, with severe lung damage implicating highly restricted gas exchange. Four more cases presented with either deadly pulmonary thromboembolism, severe bronchial aspiration, gastrointestinal bleeding, or signs of left ventricular heart failure (3.8 % each). All rights reserved. No reuse allowed without permission.

(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. We then determined conditions leading to these immediate causes of death (Table 2) . We found that COVID-19 or SARS-CoV-2 infection most prevalently preceded the immediate cause of death in ten cases (38.5 %), followed by bacterial pneumonia with or without abscess formation in six cases (23.1 %), pulmonary bleeding in two cases (7.7 %), and arterial thrombosis or thromboembolism also in two cases (7.7 %). In addition, we found individual cases with invasive pulmonary mycosis or gastric peptic ulcer as conditions leading to cause of death (3.8 % each).

Of note, in three cases (11.5 %) we did not find pathologies that would qualify for an intermediate between underlying and immediate cause of death.

Next, we identified underlying causes of death, i.e. diseases that initiated the events resulting in death ( Table 2 ). For this, we considered all autopsy findings and the clinical history to determine the underlying disease that would causally explain conditions leading to cause of death and immediate causes of death in all cases. We determined COVID-19 pneumonia as underlying cause of death in the majority of decedents (53.8%). Of note, when considering COVID-19 or SARS-CoV-2 infection as underlying cause of death or condition leading to cause of death, this applied to a total of 24 cases (92.3 %). Preexisting lung emphysema, pulmonary hypertension, and chronic right ventricular insufficiency were considered as diseases underlying cause of death in 26.9 %. In two cases (7.7 %), cardiovascular disease, and in two further cases (7.7 %), malignant tumors or consequences of tumor therapy were considered as underlying disease.

Collectively, our findings demonstrate that septic organ failure, pneumonia, respiratory insufficiency, and right ventricular heart failure due to COVID-19 were the most frequent pathological mechanisms of death in these patients.

To learn about other relevant disease conditions in patients that died after SARS-CoV-2 infection, we determined the presence and extent of comorbidities by autopsy ( Table 2) .

Generalized atherosclerosis was present in all but one case (96.2%), and was mild in 9 (34.6 %), moderate in 3 (11.5 %) and severe in 13 cases (50 %). Similarly, coronary artery disease was seen in all but two cases (92.3 %), and was mild in 8 (30.8 %), moderate in 4 (15.4 %) and severe in 11 decedents (42.3 %). Furthermore, we noticed preexisting emphysema of the lungs in almost half of the cases (46.2 %), and pulmonary artery sclerosis as a sign of pulmonary hypertension in 11 cases (42.3 %). Other comorbidities included myocardial hypertrophy (65.4%), hepatosteatosis (11.5%) and liver fibrosis (7.7%). In two cases (7.7 %), we defined COVID-19 or SARS-CoV-2 as comorbidity, since we did not observe a direct contribution of this All rights reserved. No reuse allowed without permission.

(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted June 17, 2020. . https://doi.org/10.1101/2020.06. 15.20131540 doi: medRxiv preprint infection to the mechanism of death. These findings demonstrated a high prevalence of cardiovascular and pulmonary comorbidities in patients that had died after COVID-19.

All rights reserved. No reuse allowed without permission.

(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. 

Here, we present data on causes of death and comorbidities in patients that had died after a severe course of COVID-19. These patients had reached a median age of 70 years, which in line with previous reports indicates increased risks for fatal COVID-19 outcome with older age 12, 13 . Clinical records showed that in the majority of cases, respiratory insufficiency was a dominating symptom, while the most frequent clinical cause of death was sepsis and thus infection related. In line with these findings, we found by autopsy that sepsis caused by purulent bacterial lung infection was the most frequent cause of death, while, in some cases, we observed deadly respiratory insufficiency due to diffuse alveolar damage. These findings suggested that SARS-CoV-2 infection could directly cause lethal lung damage. However, death due to pulmonary bacterial superinfection and sepsis appeared to be a more common causal chain of events that may significantly endanger patients with severe COVID-19-related lung damage. We hypothesize that such causality may be even more prevalent in clinical settings where respiratory insufficiency is manageable by mechanical ventilation or extracorporeal oxygenation.

A recent study showed high frequencies of fatal pulmonary thromboembolism in patients that had died of COVID-19 10 . Deep venous thrombosis was identified as the likely thromboembolic source. In line with these findings, pulmonary thromboembolism was diagnosed in almost every fourth of our patients during the clinical course of the disease. However, we found that pulmonary thromboembolism was an immediate cause of death or a condition leading to cause of death in two cases only, which suggests that in other cases hypercoagulability may have been effectively controlled by anti-coagulant treatment. Nevertheless, hypercoagulability appears to be an important, severe and potentially fatal aspect of COVID-19 14, 15 . Furthermore, peripheral microthrombosis in multiple organ systems has been reported 16 The majority of deceased patients in our study had diagnosed comorbidities that with arterial hypertension, chronic kidney or heart disease, and chronic pulmonary disease most frequently affected the cardiovascular and respiratory system. By autopsy, we confirmed these clinical diagnoses, since we found their pathological correlates that included general and coronary atherosclerosis, cardiac hypertrophy, and pulmonary emphysema amongst others. In addition, we found a high prevalence of lifestyle risk factors, such as obesity, alcohol consumption, and nicotine abuse. These findings are in agreement with previous studies and imply that patients All rights reserved. No reuse allowed without permission.

(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted June 17, 2020. . https://doi.org/10.1101/2020.06.15.20131540 doi: medRxiv preprint with preexisting chronic health conditions or lifestyle risk factors are at an increased risk for fatal outcome of COVID-19 17, 18 . However, considering both the high frequency of these comorbidities and the relatively high age of patients that died after SARS-CoV-2 infection, this led to a reasonable debate about the extent to which preexisting health conditions or COVID-19 determined the time of death 19 , and our data may further inform about this issue. We found that sepsis due to lung infections and respiratory insufficiency were the most frequent immediate causes of death. However, our autopsy series included no single case of immediate deadly ischemic heart disease or stroke, which are the most common causes of death worldwide 20 , and for which the majority of comorbidities as well as the mentioned life style risk factors that we found were strongly predisposing 21 . This indicates that the immediate causes of death appear not to be caused directly from the observed comorbidities but instead were directly linked to lung damage initiated by SARS-CoV-2 infection in most cases. Our data therefore suggest that in the majority of our cases with severe and fatal COVID-19, patients had died of this disease, although in the presence of multiple preexisting health conditions. These findings also support the idea that patients who died of COVID-19 appear to have lost considerable lifetime, independent of their age, as reported by others 19 .

A limitation of our study is the relatively small sample size. Furthermore, patients included in this study had reached a median age of 70 years, which mirrors reported age distributions of inpatient non-survivors in Wuhan 12 , and data from a recent autopsy report 16 , but is lower than suggested by other epidemiologic data from Italy on COVID-19 decedents 22 . While regional factors may influence age distribution, this discrepancy also suggests a case selection bias, and we speculate this may reflect which patients were hospitalized and therefore received most intense therapeutic measures. The interpretation of autopsy results and conclusions on health impacts of COVID-19 therefore requires careful consideration of the study population. All rights reserved. No reuse allowed without permission.

(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted June 17, 2020. .

Wichmann (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted June 17, 2020. . 

An interactive web-based dashboard to track COVID-19 in real time

WHO Director-General's remarks at the media briefing on 2019-nCoV on 11

COVID-19 situation update for the EU/EEA and the UK, as of 13

Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72314 Cases From the Chinese Center for Disease Control and Prevention

Baseline Characteristics and Outcomes of 1591 Patients Infected With SARS-CoV-2 Admitted to ICUs of the Lombardy Region, Italy

Initial ELSO Guidance Document: ECMO for COVID-19 Patients with Severe Cardiopulmonary Failure

Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study

Infection fatality rate of SARS-CoV-2 infection in a German community with a super-spreading event

Cardiovascular Disease, Drug Therapy, and Mortality in Covid-19

Incidence of thrombotic complications in critically ill ICU patients with COVID-19

High risk of thrombosis in patients with severe SARS-CoV-2 infection: a multicenter prospective cohort study

Pathophysiology of SARS-CoV-2: targeting of endothelial cells renders a complex disease with thrombotic microangiopathy and aberrant immune response. The Mount Sinai COVID-19 autopsy experience

Factors associated with hospital admission and critical illness among 5279 people with coronavirus disease 2019 in New York City: prospective cohort study

Preliminary Estimates of the Prevalence of Selected Underlying Health Conditions Among Patients with Coronavirus Disease 2019 -United States

COVID-19 -exploring the implications of longterm condition type and extent of multimorbidity on years of life lost: a modelling study

The top 10 causes of death

General cardiovascular risk profile for use in primary care: the Framingham Heart Study

Case-Fatality Rate and Characteristics of Patients Dying in Relation to COVID-19 in Italy

We are indebted to Anistan Sebastiampillai, Juliane Plaschke and Francisca Egelhofer for excellent technical assistance and helpful advice. The authors declare no conflicts of interest.